• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

byMonica ParksandAndrew Bishara
June 1, 2014
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Most treatment-naïve patients with chronic lymphocytic leukemia (CLL) safely tolerated escalating doses of combined lenalidomide and rituximab.

2. Younger patients showed higher response rates but similar progression free survival compared to older patients.

Evidence rating level: 1 (Excellent)

Study rundown: Some patients with chronic lymphocytic leukemia (CLL), particularly older patients and those with comorbidities, do not tolerate intensive chemotherapy regimens well. Lenalidomide, an immunomodulatory drug, has been shown to be active against CLL, and combinations of Lenalidomide and Rituximab have demonstrated some effectiveness in relapsed CLL. At the conclusion of this Phase II trial, the authors found that intrapatient dose-escalation of combined lenalidomide and rituximab was safe for patients naïve to treatment with chemotherapy. Furthermore, most patients reached the maximum dose and demonstrated some response. Based off these results, the authors suggest that lenalidomide and rituximab together present an immune-based alternative approach to the management of treatment-naïve CLL patients.

Click to read the study in JCO

Relevant Reading: Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

RELATED REPORTS

Accelerated approval drugs incur significant fee-for-service Medicare costs

Unsweetened coffee consumption is associated with reduced risk of mortality

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

In-Depth [phase II prospective clinical trial]: For this phase II clinical trial, the authors enrolled 69 treatment-naïve patients with chronic lymphocytic leukemia into one of two age-specific strata: those less than 65 years old (mean age 56) and those greater than 65 years old (mean age 70). All patients started at 2.5 mg/day lenalidomide and then escalated based on tolerability to a maximum of 10mg/day for a maximum of 7 21 day cycles. Rituximab was started at the end of cycle 1 and continued for 7 cycles. Median follow-up was more than 20 months. The primary outcome was the complete response rate for each age group, and secondary outcomes drug safety, overall response rate, progression free survival and overall survival. These two arms differed in that patients in the older patient stratum more frequently had elevated serum beta-2 microglobulin levels, high-risk Rai stage, and were less likely to complete maximum number of cycles. The response rate also differed: 95% with 20% complete responses and 20% nodular partial responses in the younger age group and 78% response rate with 11% complete responses in the older age strata. Progression-free survival did not differ significantly, with 19 months for the younger cohort and 20 months for the older group.

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: chemotherapychronic lymphocytic leukemiaCLLlenalidomideoncologyrituximab
Previous Post

Chemoembolization comparable to standard-of-care for small hepatocellular cancers

Next Post

Overall improvement in management of high blood pressure between 1994 and 2011

RelatedReports

Estrogen withdrawal associated with perimenopausal depression
Oncology

Accelerated approval drugs incur significant fee-for-service Medicare costs

June 22, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

May 26, 2022
Next Post
Low diastolic blood pressure associated with higher mortality in chronic kidney disease

Overall improvement in management of high blood pressure between 1994 and 2011

Assisted conception not associated with increased pediatric cancer risk

Comparable outcomes for embryo transfers by fellows versus attending physicians

Women electing abortion more likely to be victims of domestic violence

Low screening rates for smokeless tobacco use in pregnant women

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.